BRIEF RESEARCH REPORT article
Front. Cardiovasc. Med.
Sec. Intensive Care Cardiovascular Medicine
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1577847
"Intracoronary Levosimendan in Neonatal Cardiac Surgery: A Retrospective Study on Hemodynamic Effects and Catecholamine-Sparing Outcomes"
Provisionally accepted
- Other, Астана, Kazakhstan
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Levosimendan is a calcium-sensitizing inotrope with vasodilatory properties, shown to improve cardiac output and reduce mortality in adults with advanced heart failure. However, data on its safety and efficacy in neonatal cardiac surgery are limited.Objective: To evaluate the intraoperative use of levosimendan in neonates with complex congenital heart defects (CHDs) undergoing open-heart surgery.Methods: We conducted a retrospective observational study of 59 neonates aged 2-30 days who underwent surgical correction of complex CHDs with cardiopulmonary bypass. Levosimendan was administered intracoronarily as part of the blood cardioplegia protocol in doses of 25-45 mcg/kg.Results: Compared to historical controls, the levosimendan group demonstrated a significant reduction in postoperative catecholamine requirements, including adrenaline and norepinephrine. In 12% of cases, surgery was completed without the use of any catecholamines. No rhythm disturbances were observed. The positive inotropic effect lasted up to 72 hours without systemic hypotension. Median adrenaline doses were significantly lower (p < 0.05), and norepinephrine use was reduced from 12% to 5%.Conclusions: Intracoronary administration of levosimendan during neonatal cardiac surgery appears to reduce catecholamine dependence and support myocardial recovery without causing rhythm disturbances or hypotension. Further randomized controlled trials are needed to validate these findings.Levosimendan is indicated for the short-term management of acute decompensated chronic heart failure in cases where standard therapy proves ineffective and inotropic support is required.
Keywords: cardiac surgery, congenital heart disease, Hemodynamics, levosimendan, neonates, Calcium sensitizer
Received: 27 Feb 2025; Accepted: 30 Jul 2025.
Copyright: © 2025 Zhauarova, Ibraev, Kerimkulov, Rakhimova and Sungkarbekov. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Gulmira Zhauarova, Other, Астана, Kazakhstan
Talgat Ibraev, Other, Астана, Kazakhstan
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.